サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：スタチンの世界市場：増加し続けるコレステロール関連の問題が、市場企業に利益をもたらす
市場調査レポート
商品コード
1158522

スタチンの世界市場：増加し続けるコレステロール関連の問題が、市場企業に利益をもたらす

Market Study on Statins: Continuously Rising Cholesterol-related Issues to Benefit Market Players
出版日: | 発行: Persistence Market Research | ページ情報: 英文 250 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
スタチンの世界市場：増加し続けるコレステロール関連の問題が、市場企業に利益をもたらす
出版日: 2022年09月16日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のスタチン市場について調査分析し、2022年～2032年の予測期間における、市場概要、動向、セグメント別・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類法
  • 市場の定義/範囲/制限

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品イノベーション・開発動向

第4章 主要な成功要因

  • 製品採用・利用分析
  • 製品のUSP/機能
  • 戦略的プロモーション戦略

第5章 世界のスタチン市場の需要分析と予測

  • 過去の市場分析
  • 現在・将来の市場予測
  • 前年比成長率動向分析

第6章 世界のスタチン市場：価格分析

  • 地域価格分析：薬剤クラス別
  • 世界平均価格分析ベンチマーク

第7章 世界のスタチン市場の需要分析と予測

  • 過去の市場分析
  • 現在・将来の市場予測
    • 前年比成長率動向分析

第8章 市場の背景

  • マクロ経済要因
    • 世界のGDP成長見通し
    • 世界の業界付加価値の概要
    • 世界のインフラ投資の概要
    • 世界の建設支出分析
    • その他のマクロ経済要因
  • 予測要因：関連性と影響
    • 主要企業の成長履歴
    • GDP成長予測
    • 建設業界の予測
    • エンドユーザーの成長見通し
    • コラボレーション活動
  • バリューチェーン
    • 原材料サプライヤー
    • メーカー一覧
    • 代理店一覧
  • COVID-19危機：影響評価
    • 現在の統計
    • 短・中・長期の見通し
    • リバウンドの可能性あり
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会分析
    • 動向

第9章 世界のスタチン市場分析と予測：薬剤クラス別

  • イントロダクション/主要な調査結果
  • 過去の市場・数量分析：タイプ別
  • 現在・将来の市場・数量分析と予測：薬剤クラス別
    • アストロバスタチン
    • フルバスタチン
    • ロバスタチン
    • プラバスタチン
    • シンバスタチン
    • その他
  • 市場の魅力分析：薬剤クラス別

第10章 世界のスタチン市場分析と予測：治療法別

  • イントロダクション/主要な調査結果
  • 過去の市場・数量分析：治療法別
  • 現在・将来の市場・数量分析と予測：治療法別
    • 心血管疾患
    • 肥満
    • 炎症性疾患
    • その他
  • 市場の魅力分析：治療法別

第11章 世界のスタチン市場分析と予測：エンドユーザー別

  • イントロダクション/主要な調査結果
  • 過去の市場・数量分析：エンドユーザー別
  • 現在・将来の市場・数量分析と予測：エンドユーザー別
    • 病院
    • クリニック
  • 市場の魅力分析：エンドユーザー別

第12章 世界のスタチン市場分析と予測：地域別

  • イントロダクション
  • 過去の市場・数量分析：地域別
  • 現在の市場・数量分析と予測：地域別
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア・太平洋
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第13章 北米のスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第14章 ラテンアメリカのスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第15章 欧州のスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第16章 南アジア・太平洋のスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第17章 東アジアのスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第18章 中東・アフリカのスタチン市場分析と予測

  • イントロダクション
  • 価格分析
  • 過去の市場・数量動向分析：市場分類別
  • 市場・数量予測：市場分類別
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場の魅力分析
    • 国別
    • タイプ別
    • 治療法別
    • エンドユーザー別
  • 市場動向
  • 主要な市場企業：強度マッピング
  • 促進要因と抑制要因：影響分析

第19章 新興国のスタチン市場分析

  • イントロダクション
    • 市場価値比率分析：主要国別
    • 世界と国の成長比較
  • 米国
  • カナダ
  • メキシコ
  • ブラジル
  • ドイツ
  • イタリア
  • フランス
  • 英国
  • スペイン
  • BENELUX
  • ロシア
  • 中国
  • 日本
  • 韓国
  • インド
  • ASEAN
  • オーストラリア・ニュージーランド
  • GCC諸国
  • トルコ
  • 北アフリカ
  • 南アフリカ

第20章 市場構造分析

  • 市場分析：企業層別（直鎖アルファオレフィン）
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Pfizer Inc.
    • AstraZeneca plc
    • Novartis International AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Biocon
    • Aurobindo Pharma Ltd
    • Concord Biotech

第22章 前提条件と使用されている頭字語

第23章 調査手法

図表

List of Tables

  • Table 01: Global Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 02: Global Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 03: Global Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 04: Global Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Region, 2017- 2032
  • Table 05: North America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
  • Table 06: North America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 07: North America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 08: North America Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 09: Latin America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
  • Table 10: Latin America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 11: Latin America Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 12: Latin America Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 13: Europe Statins Market Volume ('000 Units) Forecast by Country 2017- 2032
  • Table 14: Europe Statins Market Value(US $ Mn) Forecast by Country, 2017- 2032
  • Table 15: Europe Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 16: Europe Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 17: Europe Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 18: South Asia & Pacific Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country,2017- 2032
  • Table 19: South Asia & Pacific Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 20: South Asia & Pacific Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 21: South Asia & Pacific Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 22: East Asia Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
  • Table 23: East Asia Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 24: East Asia Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 25: East Asia Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032
  • Table 26: Middle East & Africa Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country, 2017- 2032
  • Table 27: Middle East & Africa Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Drug Class, 2017- 2032
  • Table 28: Middle East & Africa Statins Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapeutic Treatment, 2017- 2032
  • Table 29: Middle East & Africa Statins Market Volume ('000 Units) & Value(US$ Mn) Forecast by End User, 2017- 2032

List of Figures

  • Figure 01: Global Statins Market Historical Volume ('000 Units), 2017 - 2021
  • Figure 02: Global Statins Market Volume ('000 Units) Forecast, 2022 - 2032
  • Figure 03: Global Statins Market Size (2017-2021)
  • Figure 04: Global Statins Absolute $ Opportunity Analysis (2017-2032)
  • Figure 05: Global Statins Market Size (2022-2032)
  • Figure 06: Global Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 07: Global Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 08: Global Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 09: Global Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 10: Global Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 11: Global Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 12: Global Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 13: Global Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 14: Global Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 15: Global Statins Market BPS Analysis by Region- 2022 & 2032
  • Figure 16: Global Statins Market Y-o-Y Growth by Region, 2021- 2032
  • Figure 17: Global Statins Market Attractiveness Analysis by Region, 2022- 2032
  • Figure 18: North America Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 19: North America Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 20: North America Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 21: North America Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 22: North America Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 23: North America Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 24: North America Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 25: North America Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 26: North America Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 27: North America Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 28: North America Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 29: North America Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 30: Latin America Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 31: Latin America Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 32: Latin America Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 33: Latin America Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 34: Latin America Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 35: Latin America Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 36: Latin America Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 37: Latin America Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 38: Latin America Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 39: Latin America Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 40: Latin America Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 41: Latin America Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 42: Europe Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 43: Europe Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 44: Europe Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 45: Europe Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 46: Europe Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 47: Europe Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 48: Europe Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 49: Europe Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 50: Europe Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 51: Europe Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 52: Europe Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 53: Europe Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 54: South Asia & Pacific Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 55: South Asia & Pacific Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 56: South Asia & Pacific Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 57: South Asia & Pacific Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 58: South Asia & Pacific Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 59: South Asia & Pacific Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 60: South Asia & Pacific Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 61: South Asia & Pacific Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 62: South Asia & Pacific Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 63: South Asia & Pacific Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 64: South Asia & Pacific Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 65: South Asia & Pacific Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 66: East Asia Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 67: East Asia Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 68: East Asia Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 69: East Asia Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 70: East Asia Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 71: East Asia Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 72: East Asia Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 73: East Asia Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 74: East Asia Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 75: East Asia Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 76: East Asia Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 77: East Asia Statins Market Attractiveness Analysis by End User, 2022- 2032
  • Figure 78: Middle East & Africa Statins Market BPS Analysis by Country- 2022 & 2032
  • Figure 79: Middle East & Africa Statins Market Y-o-Y Growth by Country, 2021- 2032
  • Figure 80: Middle East & Africa Statins Market Attractiveness Analysis by Country, 2022- 2032
  • Figure 81: Middle East & Africa Statins Market BPS Analysis by Drug Class- 2022 & 2032
  • Figure 82: Middle East & Africa Statins Market Y-o-Y Growth by Drug Class, 2021- 2032
  • Figure 83: Middle East & Africa Statins Market Attractiveness Analysis by Drug Class, 2022- 2032
  • Figure 84: Middle East & Africa Statins Market BPS Analysis by Therapeutic Treatment- 2022 & 2032
  • Figure 85: Middle East & Africa Statins Market Y-o-Y Growth by Therapeutic Treatment, 2021- 2032
  • Figure 86: Middle East & Africa Statins Market Attractiveness Analysis by Therapeutic Treatment, 2022- 2032
  • Figure 87: Middle East & Africa Statins Market BPS Analysis by End User- 2022 & 2032
  • Figure 88: Middle East & Africa Statins Market Y-o-Y Growth by End User, 2021- 2032
  • Figure 89: Middle East & Africa Statins Market Attractiveness Analysis by End User, 2022- 2032
目次
Product Code: PMRREP3038

Report Scope:

The latest market report by Persistence Market Research on the global statins market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Statins. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global statins market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the statins market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research's report on the global statins market offers information divided into four segments - drug class, therapeutic treatment, end user and region.

Drug Class

Astrovastatin

Fluvastatin

Lovastatin

Pravastatin

Simvastatin

Others

Therapeutic Treatment

Cardiovascular Disorders

Obesity

Inflammatory Disorders

Others

End User

Hospitals

Clinics

Region

North America

Latin America

Europe

South Asia and Pacific

East Asia

Middle East and Africa

Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?

Which region is experiencing the highest growth (CAGR)?

Which factors are impacting the global statins industry?

What are the global trends impacting the market?

What strategies must emerge players adopt to capture opportunities in various regions in the market?

What is the structure of the global statins market?

Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global statins market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions - North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research

Secondary Research

Trade Research

Social Media Research

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Strategic Promotional Strategies

5. Global Statins Market Demand Analysis 2017-2021 and Forecast, 2022-2032

  • 5.1. Historical Market Volume (Tons) Analysis, 2017-2021
  • 5.2. Current and Future Market Volume (Tons) Projections, 2022-2032
  • 5.3. Y-o-Y Growth Trend Analysis

6. Global Statins Market - Pricing Analysis

  • 6.1. Regional Pricing Analysis By Drug Class
  • 6.2. Global Average Pricing Analysis Benchmark

7. Global Statins Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

  • 8.1. Macro-Economic Factors
    • 8.1.1. Global GDP Growth Outlook
    • 8.1.2. Global Industry Value Added Overview
    • 8.1.3. Global Infrastructure Investment Overview
    • 8.1.4. Global Construction Spending Analysis
    • 8.1.5. Other Macro Economic Factors
  • 8.2. Forecast Factors - Relevance & Impact
    • 8.2.1. Top Companies Historical Growth
    • 8.2.2. GDP Growth forecast
    • 8.2.3. Construction Industry forecast
    • 8.2.4. End User Growth Outlook
    • 8.2.5. Collaboration Activities
  • 8.3. Value Chain
    • 8.3.1. Raw Material Suppliers
    • 8.3.2. List of Manufacturers
    • 8.3.3. List of Distributors
  • 8.4. COVID-19 Crisis - Impact Assessment
    • 8.4.1. Current Statistics
    • 8.4.2. Short-Mid-Long Term Outlook
    • 8.4.3. Likely Rebound
  • 8.5. Market Dynamics
    • 8.5.1. Drivers
    • 8.5.2. Restraints
    • 8.5.3. Opportunity Analysis
    • 8.5.4. Trends

9. Global Statins Market Analysis 2017-2021 and Forecast 2022-2032, by Drug Class

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017-2021
  • 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Drug Class 2022-2032
    • 9.3.1. Astrovastatins
    • 9.3.2. Fluvastatins
    • 9.3.3. Lovastatins
    • 9.3.4. Pravastatins
    • 9.3.5. Simvastatins
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis by Drug Class

10. Global Statins Market Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Treatment

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Therapeutic Treatment, 2017-2021
  • 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Therapeutic Treatment, 2022-2032
    • 10.3.1. Cardiovascular Disorders
    • 10.3.2. Obesity
    • 10.3.3. Inflammatory Disorders
    • 10.3.4. Others
  • 10.4. Market Attractiveness Analysis By Therapeutic Treatment

11. Global Statins Market Analysis 2017-2021 and Forecast 2022-2032, By End User

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) and Volume Analysis By End User, 2017-2021
  • 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By End User 2022-2032
    • 11.3.1. Hospitals
    • 11.3.2. Clinics
  • 11.4. Market Attractiveness Analysis By End User

12. Global Statins Market Analysis 2017-2021 and Forecast 2022-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017-2021
  • 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia and Pacific
    • 12.3.6. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 13.4.1. By Country
      • 13.4.1.1. U.S.
      • 13.4.1.2. Canada
    • 13.4.2. By Type
    • 13.4.3. By Therapeutic Treatment
    • 13.4.4. By End User
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Type
    • 13.5.3. By Therapeutic Treatment
    • 13.5.4. By End User
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. Latin America Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 14.4.1. By Country
      • 14.4.1.1. Brazil
      • 14.4.1.2. Mexico
      • 14.4.1.3. Rest of Latin America
    • 14.4.2. By Type
    • 14.4.3. By Therapeutic Treatment
    • 14.4.4. By End User
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Type
    • 14.5.3. By Therapeutic Treatment
    • 14.5.4. By End User
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. Europe Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 15.1. Introduction
  • 15.2. Pricing Analysis
  • 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 15.4.1. By Country
      • 15.4.1.1. Germany
      • 15.4.1.2. Italy
      • 15.4.1.3. France
      • 15.4.1.4. U.K.
      • 15.4.1.5. Spain
      • 15.4.1.6. BENELUX
      • 15.4.1.7. Russia
      • 15.4.1.8. Rest of Europe
    • 15.4.2. By Type
    • 15.4.3. By Therapeutic Treatment
    • 15.4.4. By End User
  • 15.5. Market Attractiveness Analysis
    • 15.5.1. By Country
    • 15.5.2. By Type
    • 15.5.3. By Therapeutic Treatment
    • 15.5.4. By End User
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 16.1. Introduction
  • 16.2. Pricing Analysis
  • 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 16.4.1. By Country
      • 16.4.1.1. India
      • 16.4.1.2. ASEAN
      • 16.4.1.3. Oceania
      • 16.4.1.4. Rest of South Asia & Pacific
    • 16.4.2. By Type
    • 16.4.3. By Therapeutic Treatment
    • 16.4.4. By End User
  • 16.5. Market Attractiveness Analysis
    • 16.5.1. By Country
    • 16.5.2. By Type
    • 16.5.3. By Therapeutic Treatment
    • 16.5.4. By End User
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. East Asia Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 17.1. Introduction
  • 17.2. Pricing Analysis
  • 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 17.4.1. By Country
      • 17.4.1.1. China
      • 17.4.1.2. Japan
      • 17.4.1.3. South Korea
    • 17.4.2. By Type
    • 17.4.3. By Therapeutic Treatment
    • 17.4.4. By End User
  • 17.5. Market Attractiveness Analysis
    • 17.5.1. By Country
    • 17.5.2. By Type
    • 17.5.3. By Therapeutic Treatment
    • 17.5.4. By End User
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Statins Market Analysis 2017-2021 and Forecast 2022-2032

  • 18.1. Introduction
  • 18.2. Pricing Analysis
  • 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
  • 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
    • 18.4.1. By Country
      • 18.4.1.1. GCC Countries
      • 18.4.1.2. Turkey
      • 18.4.1.3. Northern Africa
      • 18.4.1.4. South Africa
      • 18.4.1.5. Rest of Middle East and Africa
    • 18.4.2. By Type
    • 18.4.3. By Therapeutic Treatment
    • 18.4.4. By End User
  • 18.5. Market Attractiveness Analysis
    • 18.5.1. By Country
    • 18.5.2. By Type
    • 18.5.3. By Therapeutic Treatment
    • 18.5.4. By End User
  • 18.6. Market Trends
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Statins Market Analysis

  • 19.1. Introduction
    • 19.1.1. Market Value Proportion Analysis, By Key Countries
    • 19.1.2. Global Vs. Country Growth Comparison
  • 19.2. U.S. Statins Market Analysis
    • 19.2.1. By Type
    • 19.2.2. By Therapeutic Treatment
    • 19.2.3. By End User
  • 19.3. Canada Statins Market Analysis
    • 19.3.1. By Type
    • 19.3.2. By Therapeutic Treatment
    • 19.3.3. By End User
  • 19.4. Mexico Statins Market Analysis
    • 19.4.1. By Type
    • 19.4.2. By Therapeutic Treatment
    • 19.4.3. By End User
  • 19.5. Brazil Statins Market Analysis
    • 19.5.1. By Type
    • 19.5.2. By Therapeutic Treatment
    • 19.5.3. By End User
  • 19.6. Germany Statins Market Analysis
    • 19.6.1. By Type
    • 19.6.2. By Therapeutic Treatment
    • 19.6.3. By End User
  • 19.7. Italy Statins Market Analysis
    • 19.7.1. By Type
    • 19.7.2. By Therapeutic Treatment
    • 19.7.3. By End User
  • 19.8. France Statins Market Analysis
    • 19.8.1. By Type
    • 19.8.2. By Therapeutic Treatment
    • 19.8.3. By End User
  • 19.9. U.K. Statins Market Analysis
    • 19.9.1. By Type
    • 19.9.2. By Therapeutic Treatment
    • 19.9.3. By End User
  • 19.10. Spain Statins Market Analysis
    • 19.10.1. By Type
    • 19.10.2. By Therapeutic Treatment
    • 19.10.3. By End User
  • 19.11. BENELUX Statins Market Analysis
    • 19.11.1. By Type
    • 19.11.2. By Therapeutic Treatment
    • 19.11.3. By End User
  • 19.12. Russia Statins Market Analysis
    • 19.12.1. By Type
    • 19.12.2. By Therapeutic Treatment
    • 19.12.3. By End User
  • 19.13. China Statins Market Analysis
    • 19.13.1. By Type
    • 19.13.2. By Therapeutic Treatment
    • 19.13.3. By End User
  • 19.14. Japan Statins Market Analysis
    • 19.14.1. By Type
    • 19.14.2. By Therapeutic Treatment
    • 19.14.3. By End User
  • 19.15. S. Korea Statins Market Analysis
    • 19.15.1. By Type
    • 19.15.2. By Therapeutic Treatment
    • 19.15.3. By End User
  • 19.16. India Statins Market Analysis
    • 19.16.1. By Type
    • 19.16.2. By Therapeutic Treatment
    • 19.16.3. By End User
  • 19.17. ASEAN Statins Market Analysis
    • 19.17.1. By Type
    • 19.17.2. By Therapeutic Treatment
    • 19.17.3. By End User
  • 19.18. Australia and New Zealand Statins Market Analysis
    • 19.18.1. By Type
    • 19.18.2. By Therapeutic Treatment
    • 19.18.3. By End User
  • 19.19. GCC Countries Statins Market Analysis
    • 19.19.1. By Type
    • 19.19.2. By Therapeutic Treatment
    • 19.19.3. By End User
  • 19.20. Turkey Statins Market Analysis
    • 19.20.1. By Type
    • 19.20.2. By Therapeutic Treatment
    • 19.20.3. By End User
  • 19.21. Northern Africa Statins Market Analysis
    • 19.21.1. By Type
    • 19.21.2. By Therapeutic Treatment
    • 19.21.3. By End User
  • 19.22. South Africa Statins Market Analysis
    • 19.22.1. By Type
    • 19.22.2. By Therapeutic Treatment
    • 19.22.3. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.1.4. Sales Footprint
      • 21.3.1.5. Strategy Overview
    • 21.3.2. AstraZeneca plc
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.2.4. Sales Footprint
      • 21.3.2.5. Strategy Overview
    • 21.3.3. Novartis International AG
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.3.4. Sales Footprint
      • 21.3.3.5. Strategy Overview
    • 21.3.4. GlaxoSmithKline plc
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.4.4. Sales Footprint
      • 21.3.4.5. Strategy Overview
    • 21.3.5. Merck & Co., Inc.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.5.4. Sales Footprint
      • 21.3.5.5. Strategy Overview
    • 21.3.6. Biocon
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.6.4. Sales Footprint
      • 21.3.6.5. Strategy Overview
    • 21.3.7. Aurobindo Pharma Ltd
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.7.4. Sales Footprint
      • 21.3.7.5. Strategy Overview
    • 21.3.8. Concord Biotech
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.8.4. Sales Footprint
      • 21.3.8.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology